ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

ELAB vs BRTX // RETURN ON INVESTED CAPITAL (ROIC)

PMGC Holdings Inc. (NASDAQ) VS. BioRestorative Therapies Inc. (NV) (NASDAQ) • 15-METRIC TALLY: ELAB 2 — BRTX 2
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ELAB VS. BRTX) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC ELAB BRTX SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 31.40% 93.40% -62.00 BRTX /gross-margins <GO>
Return on Invested Capital (ROIC) ACTIVE -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield — — — TIE /fcf-yield <GO>
Operating Margin — -60.00% — TIE /operating-margins <GO>
Net Profit Margin -60.00% -60.00% 0.00 TIE /net-margins <GO>
Revenue Growth (YoY) — -10.30% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 3/9 2/9 +1.00 ELAB /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 27.2 31.9 -4.70 BRTX /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $2.1M $1.9M $170.9K ELAB /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR ELAB REV BRTX REV ELAB GROSS % BRTX GROSS % ELAB FCF BRTX FCF
FY 2025 $590.1K $359.7K 31.4% 93.4% -$6.4M -$10.9M
FY 2024 $3.8M $401.0K — 93.0% -$5.5M -$8.3M
FY 2023 $1.7M $145.8K — — -$4.6M -$6.4M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ELAB // BETA —
BRTX // BETA —